GSK’s ViiV to lean on long-acting HIV portfolio ahead of dolutegravir patent expiration

GSK’s ViiV Healthcare is eyeing 2026 and 2027 for potential longer-acting versions of its respective HIV injectables for prevention and treatment, executives said on a media call Wednesday.

The effort is part of GSK’s plan to bounce back from a key patent expiration in April 2028 for dolutegravir, its blockbuster…
Click here to view original post